Serpine2 as a biomarker for IgA nephropathy
US8178358B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2010 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Jan 28, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/347
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.